Fig. 2: Tumour response in the efficacy population (n = 23). | Nature Communications

Fig. 2: Tumour response in the efficacy population (n = 23).

From: Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial

Fig. 2

Waterfall plots of the best percentage change in the target lesion size from baseline to the end of the three cycles of study treatment (a) and from baseline to three weeks after the completion of the six cycles of study treatment (b). The colour indicates the type of response. The dashed line at 20% represents the boundary for the determination of progressive disease, and the dashed line at āˆ’30% represents the boundary for the determination of partial response. Source data are provided as a Source Data file.

Back to article page